MDMB-5'Br-BUTINACA explained

Iupac Name:	methyl (2S)-2-[(5-bromo-1-butylindazole-3-carbonyl)amino]-3,3-dimethylbutanoate
Width:	200px
Pubchem:	168325141
Smiles:	CCCCN1C2=C(C=C(C=C2)Br)C(=N1)C(=O)N[C@H](C(=O)OC)C(C)(C)C
C:	19
H:	26
Br:	1
N:	3
O:	3
Stdinchi:	1S/C19H26BrN3O3/c1-6-7-10-23-14-9-8-12(20)11-13(14)15(22-23)17(24)21-16(18(25)26-5)19(2,3)4/h8-9,11,16H,6-7,10H2,1-5H3,(H,21,24)/t16-/m1/s1
Stdinchikey:	NKCFVJNTALOWGJ-MRXNPFEDSA-N

MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.^{[1] [2] [3]}

See also

• 4F-MDMB-BINACA
• 6-Bromopravadoline
• ADB-PINACA
• ADB-5'F-BUTINACA
• ADB-5'Br-BUTINACA
• ADB-5'Br-PINACA
• ADSB-FUB-187
• MDMB-BINACA

Notes and References

1. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1159142/Cumyl-pegalone_and_other_uncontrolled_SCRA_report-FINAL.pdf Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
2. Yurchenko L, Pavlovets Y . Recent trends in the identification of psychoactive substances. . August 2022 . Russian . Latest Trends in the Field of Identification of Psychoactive Substances . 32 . 10.13140/RG.2.2.34906.62402 .
3. Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP . In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs . Drug Testing and Analysis . October 2023 . 37903509 . 10.1002/dta.3592 . 264671035 .